Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.
*Byth KF, Conroy LA, Howlett S, Smith AJ, May J, Alexander DR, Holmes N: CD45-null transgenic mice reveal a positive regulatory role for CD45 in early
thymocyte development, in the selection of CD4+CD8+ thymocytes, and B cell maturation. J Exp Med. 1996 Apr 1;183(4):1707-18.
[Abstract] [Full Text]
*Townsend KP, Vendrame M, Ehrhart J, Faza B, Zeng J, Town T, Tan J: CD45 isoform RB as a molecular target to oppose lipopolysaccharide-induced microglial activation in mice. Neurosci Lett. 2004 May 13;362(1):26-30.
*Dawes R, Petrova S, Liu Z, Wraith D, Beverley PC, Tchilian EZ. Combinations of CD45 isoforms are crucial for immune function and disease. J Immunol. 2006 Mar 15;176(6):3417-25. [Abstract] [Full Text]
*Desharnais P, Dupéré-Minier G, Hamelin C, Devine P, Bernier J: Involvement of CD45 in DNA fragmentation in apoptosis induced by mitochondrial perturbing agents. Apoptosis. 2007 Dec 19. [Abstract]
Product Specific References
*Shen KY, Song YC, Chen IH, Chong P, Liu SJ: Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Hum Vaccin Immunother. 2014;10(11):3241-50. [Abstract] [Full Text]